cytotoxic T cell

(redirected from Cytotoxic T-lymphocytes)
Also found in: Dictionary, Thesaurus, Medical.

cytotoxic T cell

[¦sīd·ə‚täk·sik ′tē ‚sel]
(immunology)
A type of T cell which protects against pathogens that invade host cell cytoplasm, where they cannot be bound by antibodies, by recognizing and killing the host cell before the pathogens can proliferate and escape.
References in periodicals archive ?
Viagene scientists believe that these gene therapy techniques achieve efficacy though enhanced stimulation of killer T- cells, or cytotoxic T-lymphocytes, the body's primary defense against viral infections and cancer.
The research, published in the September 1, 2002 issue of Cancer Research, shows that RNA encoding the protein component of telomerase (TERT RNA), when introduced into dendritic cells (DCs), is effective in priming telomerase-specific cytotoxic T-lymphocytes (CTLs) to target and destroy malignant tumors.
The readministration of these cells is intended to lead to a vigorous immune response of cytotoxic T-lymphocytes and antibodies against HIV.
The Company has exclusive rights to a patent, issued to the Fred Hutchinson Cancer Research Center in October 1998, related to a process for rapidly expanding cytotoxic T-lymphocytes in culture to millions or billions of cells that retain their ability to recognize specific disease-related antigens.
Utilizing Cytel's advanced understanding of the immune system's operation both in disease and in health, the Company is developing drug candidates under two distinct approaches: the immune suppression program targets inflammatory diseases and reperfusion injury through the use of cell adhesion blockers that prevent the excessive migration of white blood cells into surrounding tissue, and the immune stimulation program is directed to the development of therapeutic vaccines to treat infectious diseases and cancers by stimulating production of antigen- specific cytotoxic T-lymphocytes by the immune system.
Utilizing Cytel's advanced understanding of the immune system's operation both in disease and in health, the Company is developing drug candidates under two distinct approaches: the immune suppression program targets inflammatory diseases and reperfusion injury through use of cell adhesion blockers that prevent the excessive migration of white blood cells into surrounding tissue, and the immune stimulation program is directed to the development of therapeutic vaccines to treat infectious diseases and cancers by stimulating production of antigen-specific cytotoxic T-lymphocytes by the immune system.
The principal technology to emerge from the joint venture is the Theradigm immune stimulation technology, providing a novel therapeutic approach to selectively stimulate the human immune system to produce a disease-specific response from white blood cells, or cytotoxic T-lymphocytes (CTLs).